首页 > 最新文献

Journal of Crohn's and Colitis最新文献

英文 中文
P704 Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: The SAPPHIRE Registry P704 癌症风险炎症性肠病患者前瞻性队列中免疫抑制的安全性:SAPPHIRE 注册中心
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.0834
J. Axelrad, Y. Jiang, J. Colombel, E. Scherl, D. Lukin, S. Chang, L. Chen, S. Katz, J. Kwah, A. Swaminath, K. Sultan, C. Villagra, L. Jandorf, S. Itzkowitz
For patients with inflammatory bowel disease (IBD) and a history of cancer, retrospective studies have failed to find evidence suggesting that exposure to biologic and/or immunomodulator (IMM) agents was associated with new or recurrent cancer. The SAPPHIRE Registry was developed to prospectively examine this issue. Patients with IBD who had a confirmed first (index) cancer 5 years prior to enrollment were recruited from centers affiliated with the New York Crohn’s and Colitis Organization (NYCCO) since 2016. Patients receiving chemotherapy or radiation therapy at enrollment or recurrent cancer within the last five years were excluded. The primary outcome was the development of an incident cancer stratified by IBD therapy exposure and adjusted for index cancer stage, index cancer type, sex, smoking history, and age at index cancer in a Cox proportional hazards model. 302 patients were analyzed. Median age at IBD diagnosis was 31.5. Patients were 47% male, 88% white, and 61% never smokers. Index cancers were solid organ (138; 46%), dermatologic (100; 33%) GI (34; 11%), hematologic (27; 9%), or of other types (3; 1%); most index cancers (excluding non-melanoma skin cancer) were diagnosed as Stage 1. Following the index cancer, 90 (30%) patients were not exposed to any immunosuppression, and the other 212 were exposed to immunosuppressive therapy: 142 biologic monotherapy (anti-TNF, anti-integrin, anti-IL12/23, anti-IL23; 47%), 13 anti-metabolite monotherapy (mercaptopurine, azathioprine, methotrexate; 4%), 41 biologic + anti-metabolite combination therapy (14%), and 16 exposed to small molecules (JAK inhibitors, ozanimod; 5%). During follow-up, 46 (15%) patients developed subsequent cancers (25 new, 21 recurrent): 22 (48%) dermatologic, 15 (33%) solid, 7 (15%) GI, and 2 (4%) hematologic malignancies at a median age of 63.5. Patients not exposed to immunosuppression experienced incident cancer at a rate of 2.58/100 person-years (PY, Table). Those exposed to immunosuppression had a rate of 5.12/100 PY, representing an additional 2.54 cancers/100 PY (95% CI: 0.22, 4.85). In a time-varying Cox proportional hazards model adjusting for clinical and demographic characteristics, the adjusted hazard ratio for incident cancer for patients exposed to immunosuppressive therapy compared to unexposed patients was 1.36 (95% CI: 0.73, 2.52). Excluding non-melanoma skin cancer, the adjusted hazard ratio was 1.38 (95% CI: 0.66, 2.91). In this ongoing prospective study, we have thus far found no association between immunosuppressive IBD therapy and risk of developing new or recurrent cancer. Ongoing enrollment and follow-up, specifically for individual drug classes and cancer types, are required to confirm these findings.
对于有癌症病史的炎症性肠病(IBD)患者,回顾性研究未能发现证据表明接触生物制剂和/或免疫调节剂(IMM)与新发或复发癌症有关。SAPPHIRE 登记处的建立就是为了对这一问题进行前瞻性研究。 自 2016 年起,从纽约克罗恩病和结肠炎组织(NYCCO)下属的中心招募了入组前 5 年已确诊首次(指数)癌症的 IBD 患者。入组时正在接受化疗或放疗的患者或过去五年内癌症复发的患者除外。主要研究结果是根据IBD治疗暴露分层的癌症发病率,并在Cox比例危险模型中根据指数癌症分期、指数癌症类型、性别、吸烟史和指数癌症发生时的年龄进行调整。 共对 302 名患者进行了分析。确诊 IBD 时的中位年龄为 31.5 岁。47%的患者为男性,88%为白人,61%从不吸烟。指数癌症包括实体器官癌(138 例,占 46%)、皮肤癌(100 例,占 33%)、消化道癌症(34 例,占 11%)、血液癌(27 例,占 9%)或其他类型癌症(3 例,占 1%);大多数指数癌症(不包括非黑色素瘤皮肤癌)被诊断为 1 期。罹患指数癌症后,90 名(30%)患者未接受任何免疫抑制治疗,其他 212 名患者接受了免疫抑制治疗:142人接受了生物单药治疗(抗肿瘤坏死因子、抗整合素、抗IL12/23、抗IL23;47%),13人接受了抗代谢单药治疗(巯嘌呤、硫唑嘌呤、甲氨蝶呤;4%),41人接受了生物+抗代谢联合治疗(14%),16人接受了小分子药物治疗(JAK抑制剂、奥扎尼莫德;5%)。在随访期间,46 名患者(15%)继发癌症(25 名新发,21 名复发):22例(48%)为皮肤恶性肿瘤,15例(33%)为实体瘤,7例(15%)为消化道恶性肿瘤,2例(4%)为血液恶性肿瘤,中位年龄为63.5岁。未接受免疫抑制治疗的患者的癌症发病率为 2.58/100人年(PY,表)。暴露于免疫抑制的患者的癌症发病率为 5.12/100人年,即每 100 人年多发 2.54 例癌症(95% CI:0.22, 4.85)。在调整临床和人口统计学特征的时变考克斯比例危险模型中,与未接受免疫抑制治疗的患者相比,接受免疫抑制治疗的患者发生癌症的调整危险比为 1.36(95% CI:0.73, 2.52)。如果不包括非黑色素瘤皮肤癌,调整后的危险比为 1.38(95% CI:0.66, 2.91)。 在这项正在进行的前瞻性研究中,我们迄今尚未发现免疫抑制性 IBD 治疗与罹患新发或复发性癌症的风险之间存在关联。要证实这些发现,还需要持续的注册和随访,特别是针对个别药物类别和癌症类型的注册和随访。
{"title":"P704 Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: The SAPPHIRE Registry","authors":"J. Axelrad, Y. Jiang, J. Colombel, E. Scherl, D. Lukin, S. Chang, L. Chen, S. Katz, J. Kwah, A. Swaminath, K. Sultan, C. Villagra, L. Jandorf, S. Itzkowitz","doi":"10.1093/ecco-jcc/jjad212.0834","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.0834","url":null,"abstract":"\u0000 \u0000 \u0000 For patients with inflammatory bowel disease (IBD) and a history of cancer, retrospective studies have failed to find evidence suggesting that exposure to biologic and/or immunomodulator (IMM) agents was associated with new or recurrent cancer. The SAPPHIRE Registry was developed to prospectively examine this issue.\u0000 \u0000 \u0000 \u0000 Patients with IBD who had a confirmed first (index) cancer 5 years prior to enrollment were recruited from centers affiliated with the New York Crohn’s and Colitis Organization (NYCCO) since 2016. Patients receiving chemotherapy or radiation therapy at enrollment or recurrent cancer within the last five years were excluded. The primary outcome was the development of an incident cancer stratified by IBD therapy exposure and adjusted for index cancer stage, index cancer type, sex, smoking history, and age at index cancer in a Cox proportional hazards model.\u0000 \u0000 \u0000 \u0000 302 patients were analyzed. Median age at IBD diagnosis was 31.5. Patients were 47% male, 88% white, and 61% never smokers. Index cancers were solid organ (138; 46%), dermatologic (100; 33%) GI (34; 11%), hematologic (27; 9%), or of other types (3; 1%); most index cancers (excluding non-melanoma skin cancer) were diagnosed as Stage 1. Following the index cancer, 90 (30%) patients were not exposed to any immunosuppression, and the other 212 were exposed to immunosuppressive therapy: 142 biologic monotherapy (anti-TNF, anti-integrin, anti-IL12/23, anti-IL23; 47%), 13 anti-metabolite monotherapy (mercaptopurine, azathioprine, methotrexate; 4%), 41 biologic + anti-metabolite combination therapy (14%), and 16 exposed to small molecules (JAK inhibitors, ozanimod; 5%). During follow-up, 46 (15%) patients developed subsequent cancers (25 new, 21 recurrent): 22 (48%) dermatologic, 15 (33%) solid, 7 (15%) GI, and 2 (4%) hematologic malignancies at a median age of 63.5. Patients not exposed to immunosuppression experienced incident cancer at a rate of 2.58/100 person-years (PY, Table). Those exposed to immunosuppression had a rate of 5.12/100 PY, representing an additional 2.54 cancers/100 PY (95% CI: 0.22, 4.85). In a time-varying Cox proportional hazards model adjusting for clinical and demographic characteristics, the adjusted hazard ratio for incident cancer for patients exposed to immunosuppressive therapy compared to unexposed patients was 1.36 (95% CI: 0.73, 2.52). Excluding non-melanoma skin cancer, the adjusted hazard ratio was 1.38 (95% CI: 0.66, 2.91).\u0000 \u0000 \u0000 \u0000 In this ongoing prospective study, we have thus far found no association between immunosuppressive IBD therapy and risk of developing new or recurrent cancer. Ongoing enrollment and follow-up, specifically for individual drug classes and cancer types, are required to confirm these findings.\u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P233 Cytomegalovirus colitis in patients with moderate-to-severe Ulcerative Colitis: diagnosis, clinical impact and treatment efficacy P233 中重度溃疡性结肠炎患者的巨细胞病毒结肠炎:诊断、临床影响和疗效
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.0363
L. Melotti, M. Salice, M. Rinaldi, N. Dussias, N. Vanigli, E. Scaioli, H. Privitera Hrustemovic, F. Rizzello, P. Gionchetti
Cytomegalovirus (CMV) colitis is a serious concern worsening the prognosis of patients with ulcerative colitis (UC), involving mainly those who are not responding to immunosuppressive therapy. CMV colitis is an independent predictor of hospitalisation and surgery. Diagnosis of CMV colitis can be obtained either via immunohistochemistry (ICH) or tissue polymerase chain reaction (PCR), possibly both. We aimed to assess the prognostic impact of CMV colitis in patients with UC and the clinical utility of testing for CMV plasma-DNA reactivation. We conducted a retrospective, observational, monocentric study in our IBD center in Bologna. Consecutive patients hospitalized for moderate-to-severe ulcerative colitis from January 2020 to June 2023 were included. Patients were tested for CMV colitis at hospitalization, along with other concomitant infections. Diagnosis of CMV-colitis was made either by ICH on colonic mucosa histological samples or on resected colon specimens. Need of surgery was evaluated at 28, 180 and 365 days. Basal characteristics of patients according to the presence or absence of CMV organ disease were compared with Mann-Whitney, X2 or Fischer tests, as appropriate. A Kaplan-Meier survival analysis was calculated to verify whether antiviral treatment for CMV organ disease had an impact on avoiding surgery. A total of 135 patients were included. CMV organ disease was present in 37 (27.4%). Around half (51.4%) were diagnosed endoscopically, and 62.2% had evidence of plasma reactivation with a median of 1008 cp/mL CMV-DNA viral load (IQR 318-2980). Differences between the two groups (CMV colitis vs non CMV) included age (p = 0.004), Charlson Comorbidity Index (CCI) (p = 0.003), refractory disease (p = 0.007), and median CMV-DNA viral load (p < 0.001). Patients with CMV colitis needed surgery in 24/37 cases within 1 year from the diagnosis, compared to 41/98 in the non-CMV group. Interestingly, among the first group, 54% of cases underwent colectomy within 28 days, whereas only 34.1% underwent colectomy in the non-CMV group (p = 0.049). At multivariable analysis, steroid refractory disease, CCI and serum CMV-DNA reactivation were associated with CMV colitis. The latter had the highest OR (17.7 p < 0.001). Kaplan-Meier showed that patients who were treated with anti-viral therapy had a significant reduction of the risk of receive surgical treatment (p<0.001) [Table 1]. CMV-DNA plasma reactivation is independently associated to CMV colitis. The use of anti-viral treatment is able to reduce the risk to underwent surgery, suggesting that screening of CMV colitis is mandatory in patients with moderate-to-severe UC.
巨细胞病毒(CMV)结肠炎是溃疡性结肠炎(UC)患者预后恶化的一个严重问题,主要涉及对免疫抑制治疗无效的患者。CMV结肠炎是住院和手术的独立预测因素。CMV结肠炎的诊断可通过免疫组化(ICH)或组织聚合酶链反应(PCR)获得,也可能两者兼而有之。我们旨在评估 CMV 结肠炎对 UC 患者预后的影响,以及检测 CMV 血浆 DNA 再激活的临床实用性。 我们在博洛尼亚的 IBD 中心开展了一项回顾性、观察性、单中心研究。研究纳入了 2020 年 1 月至 2023 年 6 月期间因中度至重度溃疡性结肠炎住院的连续患者。患者在住院时接受了 CMV 结肠炎以及其他并发感染的检测。通过结肠粘膜组织学样本或切除的结肠标本上的 ICH 诊断 CMV 结肠炎。手术需求在 28 天、180 天和 365 天时进行评估。根据是否存在 CMV 器官疾病,采用 Mann-Whitney、X2 或 Fischer 检验比较患者的基本特征。计算卡普兰-梅耶生存分析,以验证针对 CMV 器官疾病的抗病毒治疗是否对避免手术有影响。 共纳入 135 名患者。其中 37 例(27.4%)存在 CMV 器官疾病。约半数(51.4%)患者经内镜确诊,62.2%的患者有血浆再激活的证据,CMV-DNA 病毒载量中位数为 1008 cp/mL(IQR 318-2980)。两组患者(CMV 结肠炎与非 CMV)之间的差异包括年龄(p = 0.004)、Charlson 生病指数(CCI)(p = 0.003)、难治性疾病(p = 0.007)和 CMV-DNA 病毒载量中位数(p < 0.001)。CMV 结肠炎患者中有 24/37 例在确诊后 1 年内需要手术治疗,而非 CMV 组中有 41/98 例。有趣的是,在第一组中,54%的病例在 28 天内接受了结肠切除术,而在非 CMV 组中,只有 34.1% 的病例接受了结肠切除术(p = 0.049)。在多变量分析中,类固醇难治性疾病、CCI 和血清 CMV-DNA 反应活化与 CMV 结肠炎有关。后者的OR值最高(17.7 p < 0.001)。Kaplan-Meier显示,接受抗病毒治疗的患者接受手术治疗的风险显著降低(P<0.001)[表1]。 CMV-DNA血浆再激活与CMV结肠炎独立相关。使用抗病毒治疗能够降低接受手术治疗的风险,这表明中重度 UC 患者必须接受 CMV 结肠炎筛查。
{"title":"P233 Cytomegalovirus colitis in patients with moderate-to-severe Ulcerative Colitis: diagnosis, clinical impact and treatment efficacy","authors":"L. Melotti, M. Salice, M. Rinaldi, N. Dussias, N. Vanigli, E. Scaioli, H. Privitera Hrustemovic, F. Rizzello, P. Gionchetti","doi":"10.1093/ecco-jcc/jjad212.0363","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.0363","url":null,"abstract":"\u0000 \u0000 \u0000 Cytomegalovirus (CMV) colitis is a serious concern worsening the prognosis of patients with ulcerative colitis (UC), involving mainly those who are not responding to immunosuppressive therapy. CMV colitis is an independent predictor of hospitalisation and surgery. Diagnosis of CMV colitis can be obtained either via immunohistochemistry (ICH) or tissue polymerase chain reaction (PCR), possibly both.\u0000 We aimed to assess the prognostic impact of CMV colitis in patients with UC and the clinical utility of testing for CMV plasma-DNA reactivation.\u0000 \u0000 \u0000 \u0000 We conducted a retrospective, observational, monocentric study in our IBD center in Bologna.\u0000 Consecutive patients hospitalized for moderate-to-severe ulcerative colitis from January 2020 to June 2023 were included. Patients were tested for CMV colitis at hospitalization, along with other concomitant infections. Diagnosis of CMV-colitis was made either by ICH on colonic mucosa histological samples or on resected colon specimens. Need of surgery was evaluated at 28, 180 and 365 days.\u0000 Basal characteristics of patients according to the presence or absence of CMV organ disease were compared with Mann-Whitney, X2 or Fischer tests, as appropriate.\u0000 A Kaplan-Meier survival analysis was calculated to verify whether antiviral treatment for CMV organ disease had an impact on avoiding surgery.\u0000 \u0000 \u0000 \u0000 A total of 135 patients were included. CMV organ disease was present in 37 (27.4%). Around half (51.4%) were diagnosed endoscopically, and 62.2% had evidence of plasma reactivation with a median of 1008 cp/mL CMV-DNA viral load (IQR 318-2980).\u0000 Differences between the two groups (CMV colitis vs non CMV) included age (p = 0.004), Charlson Comorbidity Index (CCI) (p = 0.003), refractory disease (p = 0.007), and median CMV-DNA viral load (p < 0.001).\u0000 Patients with CMV colitis needed surgery in 24/37 cases within 1 year from the diagnosis, compared to 41/98 in the non-CMV group. Interestingly, among the first group, 54% of cases underwent colectomy within 28 days, whereas only 34.1% underwent colectomy in the non-CMV group (p = 0.049).\u0000 At multivariable analysis, steroid refractory disease, CCI and serum CMV-DNA reactivation were associated with CMV colitis. The latter had the highest OR (17.7 p < 0.001).\u0000 Kaplan-Meier showed that patients who were treated with anti-viral therapy had a significant reduction of the risk of receive surgical treatment (p<0.001) [Table 1].\u0000 \u0000 \u0000 \u0000 CMV-DNA plasma reactivation is independently associated to CMV colitis. The use of anti-viral treatment is able to reduce the risk to underwent surgery, suggesting that screening of CMV colitis is mandatory in patients with moderate-to-severe UC.\u0000 \u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"311 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P193 Fatigued patients with Inflammatory Bowel Disease exhibit distinct systemic antibody epitope repertoires P193 患有炎症性肠病的疲劳患者表现出不同的全身抗体表位汇集
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.0323
M. G. Griesbaum, T. Vogl, S. Andreu-Sánchez, S. Klompus, I. N. Kalka, S. Leviatan, H. V. van Dullemen, M. Visschedijk, E. Festen, K. N. Faber, G. Dijkstra, A. Weinberger, E. Segal, R. Weersma, A. R. Bourgonje
Patients with inflammatory bowel diseases (IBD) frequently experience fatigue, affecting up to 80% of those with active disease and approximately 50% with quiescent disease. The exact cause of IBD-associated fatigue is often unknown, making clinical management very challenging. In this study we aimed to explore whether patients with quiescent IBD reporting fatigue exhibit specific systemic antibody responses, which could provide insight into immune reactivities underlying fatigue. Systemic antibody epitope repertoires were profiled in 327 patients with IBD (156 Crohn’s disease [CD]; 171 ulcerative colitis [UC]) leveraging phage-display immunoprecipitation sequencing (PhIP-Seq) against 344,000 rationally selected peptide antigens. Fatigue severity was assessed on a 10-point Likert scale, ranging from 1 (no fatigue) to 10 (highest fatigue severity). Quiescent IBD was defined as clinical (Harvey-Bradshaw Index [HBI] <5 or Simple Clinical Colitis Activity Index [SCCAI] <2.5) and biochemical remission (C-reactive protein [CRP] <5 mg/L) at time of sampling. Multivariable logistic regression analyses, allowing adjustment for potential confounding factors e.g. age, sex, and smoking, were performed to identify associations between fatigue and systemic antibody responses. A total of 105 different antibody-bound peptides were associated with fatigue (nominal P-value<0.05), albeit none passed adjustment for multiple comparisons. Among these antibodies, 50 (47.6%) were found to be less frequent in highly fatigued patients (fourth quartile, Q4), while 55 (52.4%) were identified as more frequent in highly fatigued patients compared to those with low fatigue scores (first quartile, Q1). Among highly fatigued patients, antibody responses were primarily directed towards viral antigens, notably several antigens from Epstein-Barr virus (EBV), as well as bacterial antigens, including functional proteins from Streptococcus and Staphylococcus species. Fatigued patients with CD exhibited elevated systemic antibody responses against allergens, Staphylococcus, Pseudomonas aeruginosa, and Shigella spp. Fatigued patients with UC showed higher frequencies of antibody responses against herpes simplex virus (HSV), influenza viruses, and few responses against allergens and Streptococcus bacteria. These results remained materially unchanged when repeating analyses in patients with quiescent IBD. This study may suggest a potential role of viral antigens, particularly EBV, in the pathophysiology of fatigue in patients with IBD. However, larger confirmatory studies are needed to validate these findings. PhIP-Seq may represent a valuable strategy to approach the investigation of immune responses underlying complex symptoms such as fatigue.
炎症性肠病(IBD)患者经常会感到疲劳,高达 80% 的活动期患者和大约 50% 的静止期患者会感到疲劳。IBD 相关性疲劳的确切病因往往不明,这使得临床治疗非常具有挑战性。在这项研究中,我们旨在探讨静止期 IBD 患者是否会出现特异性全身抗体反应,这将有助于深入了解疲劳背后的免疫反应。 我们利用噬菌体展示免疫沉淀测序(PhIP-Seq)技术,针对 344,000 个合理选择的多肽抗原,对 327 例 IBD 患者(156 例克罗恩病 [CD];171 例溃疡性结肠炎 [UC])的全身抗体表位谱进行了分析。疲劳严重程度采用 10 分李克特量表进行评估,从 1 分(无疲劳感)到 10 分(疲劳严重程度最高)不等。IBD静止期的定义为取样时的临床(哈维-布拉德肖指数[HBI]<5或简单临床结肠炎活动指数[SCCAI]<2.5)和生化缓解(C反应蛋白[CRP]<5 mg/L)。在对年龄、性别和吸烟等潜在混杂因素进行调整后,进行了多变量逻辑回归分析,以确定疲劳与全身抗体反应之间的关联。 共有105种不同的抗体结合肽与疲劳有关(标称P值<0.05),尽管没有一种抗体通过了多重比较调整。在这些抗体中,有 50 种(47.6%)在高度疲劳患者(第四四分位数,Q4)中出现频率较低,而有 55 种(52.4%)在高度疲劳患者中出现频率高于低度疲劳患者(第一四分位数,Q1)。在高度疲劳患者中,抗体反应主要针对病毒抗原,尤其是爱泼斯坦-巴氏病毒(EBV)的几种抗原,以及细菌抗原,包括链球菌和葡萄球菌的功能蛋白。疲劳的 CD 患者对过敏原、葡萄球菌、绿脓杆菌和志贺氏杆菌的全身抗体反应较高。疲劳的 UC 患者对单纯疱疹病毒(HSV)和流感病毒的抗体反应频率较高,而对过敏原和链球菌的反应较低。在对静止期 IBD 患者进行重复分析时,这些结果基本保持不变。 这项研究可能表明,病毒抗原(尤其是 EBV)在 IBD 患者疲劳的病理生理学中可能发挥作用。不过,还需要更大规模的确证研究来验证这些发现。PhIP-Seq可能是研究疲劳等复杂症状背后的免疫反应的一种有价值的策略。
{"title":"P193 Fatigued patients with Inflammatory Bowel Disease exhibit distinct systemic antibody epitope repertoires","authors":"M. G. Griesbaum, T. Vogl, S. Andreu-Sánchez, S. Klompus, I. N. Kalka, S. Leviatan, H. V. van Dullemen, M. Visschedijk, E. Festen, K. N. Faber, G. Dijkstra, A. Weinberger, E. Segal, R. Weersma, A. R. Bourgonje","doi":"10.1093/ecco-jcc/jjad212.0323","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.0323","url":null,"abstract":"\u0000 \u0000 \u0000 Patients with inflammatory bowel diseases (IBD) frequently experience fatigue, affecting up to 80% of those with active disease and approximately 50% with quiescent disease. The exact cause of IBD-associated fatigue is often unknown, making clinical management very challenging. In this study we aimed to explore whether patients with quiescent IBD reporting fatigue exhibit specific systemic antibody responses, which could provide insight into immune reactivities underlying fatigue.\u0000 \u0000 \u0000 \u0000 Systemic antibody epitope repertoires were profiled in 327 patients with IBD (156 Crohn’s disease [CD]; 171 ulcerative colitis [UC]) leveraging phage-display immunoprecipitation sequencing (PhIP-Seq) against 344,000 rationally selected peptide antigens. Fatigue severity was assessed on a 10-point Likert scale, ranging from 1 (no fatigue) to 10 (highest fatigue severity). Quiescent IBD was defined as clinical (Harvey-Bradshaw Index [HBI] <5 or Simple Clinical Colitis Activity Index [SCCAI] <2.5) and biochemical remission (C-reactive protein [CRP] <5 mg/L) at time of sampling. Multivariable logistic regression analyses, allowing adjustment for potential confounding factors e.g. age, sex, and smoking, were performed to identify associations between fatigue and systemic antibody responses.\u0000 \u0000 \u0000 \u0000 A total of 105 different antibody-bound peptides were associated with fatigue (nominal P-value<0.05), albeit none passed adjustment for multiple comparisons. Among these antibodies, 50 (47.6%) were found to be less frequent in highly fatigued patients (fourth quartile, Q4), while 55 (52.4%) were identified as more frequent in highly fatigued patients compared to those with low fatigue scores (first quartile, Q1). Among highly fatigued patients, antibody responses were primarily directed towards viral antigens, notably several antigens from Epstein-Barr virus (EBV), as well as bacterial antigens, including functional proteins from Streptococcus and Staphylococcus species. Fatigued patients with CD exhibited elevated systemic antibody responses against allergens, Staphylococcus, Pseudomonas aeruginosa, and Shigella spp. Fatigued patients with UC showed higher frequencies of antibody responses against herpes simplex virus (HSV), influenza viruses, and few responses against allergens and Streptococcus bacteria. These results remained materially unchanged when repeating analyses in patients with quiescent IBD.\u0000 \u0000 \u0000 \u0000 This study may suggest a potential role of viral antigens, particularly EBV, in the pathophysiology of fatigue in patients with IBD. However, larger confirmatory studies are needed to validate these findings. PhIP-Seq may represent a valuable strategy to approach the investigation of immune responses underlying complex symptoms such as fatigue.\u0000 \u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P195 Prevalence and factors associated with fatigue in patients with inflammatory bowel disease P195 炎症性肠病患者疲劳的发生率和相关因素
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.0325
H. Kallel, N. Elleuch, R. Limam, W. Dahmeni, A. Hammami, A. Braham, A. Ben Slama, H. Jaziri, M. Ksiaa
Inflammatory bowel disease (IBD) is a group of pathologies characterized by symptoms that can be distressing and incapacitating. Fatigue is one of the complaints most frequently reported by patients. However, few studies have analyzed the determinants of fatigue in IBD. The aim of our work is to estimate the prevalence of fatigue, and to identify the factors associated with it in IBD patients. Fatigue and nine other dimensions of IBD-related disability were assessed in a cross-sectional survey, including patients followed and hospitalized between March and September 2023, using the IBD-Disk questionnaire. Fatigue and severe fatigue were defined by an "Energy" sub-score > 5 and > 7 respectively. The correlation between Energy and the other IBD-Disk items was analyzed using Pearson's correlation coefficient. Determinants of fatigue were assessed using the Chi-2 test and multinomial logistic regression. We included 166 patients, 53.6% were men, and 69.3% were Crohn's disease carriers. Mean age was 39 ± 12.7 years. More than two-thirds (69.9%) lived in urban areas. IBD was active in 48.8% of cases. A total of 59% of patients were on biotherapy for maintenance treatment. The mean IBD-Disk total score was 36.4 ± 21. The Energy subscore obtained the highest score (4.9 ± 2.9). The prevalence rates for fatigue and severe fatigue were 42.2% and 22.9% respectively. Significant correlations were observed between fatigue and all other dimensions of IBD-related disability assessed by the IBD-Disk (p<0.001). The strongest correlations were observed between fatigue and defecation regulation (r=0.642), fatigue and work and study (r=0.630), and between fatigue and sleep (r=0.620) (Table 1). In univariate analysis, factors significantly associated with fatigue and severe fatigue were female gender (p=0.040 and 0.047 respectively), disease activity and hospitalization (p<0, 001 each), anemia (p=0.005 and 0.014 respectively), elevated CRP (p<0.001 and 0.030 respectively), hypoalbuminemia (p<0.001 and 0.042 respectively) and absence of biotherapy treatment (p=0.02 and 0.01 respectively). Living in an urban area was also associated with fatigue (p=0.015). In multivariate analysis, the independent risk factors predictive of fatigue were female gender, urban origin, hospitalization at the time of interview, and clinical disease activity. Independent risk factors for severe fatigue in multivariate analysis were female gender and clinical disease activity (Table 2). The causes of fatigue are multiple and go beyond the clinico-biological elements associated with IBD, also encompassing social, geographical and sleep disturbance aspects. This underlines the need for a holistic approach to the management of IBD patients.
炎症性肠病(IBD)是一组以令人痛苦和丧失工作能力的症状为特征的病症。疲劳是患者最常抱怨的症状之一。然而,很少有研究对 IBD 患者疲劳的决定因素进行分析。我们的研究旨在估算 IBD 患者疲劳的发生率,并找出与之相关的因素。 我们使用 IBD-Disk 问卷对 2023 年 3 月至 9 月间随访和住院的患者进行了横断面调查,评估了疲劳和其他九个方面的 IBD 相关残疾。疲劳和严重疲劳的定义分别是 "能量 "子分数大于 5 和大于 7。采用皮尔逊相关系数分析了 "能量 "与 IBD-Disk 其他项目之间的相关性。疲劳的决定因素采用 Chi-2 检验和多项式逻辑回归进行评估。 我们共纳入了 166 名患者,其中 53.6% 为男性,69.3% 为克罗恩病携带者。平均年龄为 39 ± 12.7 岁。超过三分之二(69.9%)的患者居住在城市地区。48.8%的病例为活动性 IBD。59%的患者接受生物疗法进行维持治疗。IBD-Disk 总分的平均值为 36.4 ± 21。能量分项得分最高(4.9 ± 2.9)。疲劳和严重疲劳的患病率分别为 42.2% 和 22.9%。疲劳与 IBD-Disk 评估的 IBD 相关残疾的所有其他维度之间存在显著相关性(P<0.001)。疲劳与排便调节(r=0.642)、疲劳与工作和学习(r=0.630)以及疲劳与睡眠(r=0.620)之间的相关性最强(表 1)。在单变量分析中,与疲劳和严重疲劳显著相关的因素有女性性别(分别为 p=0.040 和 0.047)、疾病活动性和住院(分别为 p<0.001)、贫血(分别为 p=0.005 和 0.014)、CRP 升高(分别为 p<0.001 和 0.030)、低白蛋白血症(分别为 p<0.001 和 0.042)和未接受生物治疗(分别为 p=0.02 和 0.01)。居住在城市地区也与疲劳有关(p=0.015)。在多变量分析中,可预测疲劳的独立风险因素包括女性性别、城市籍贯、受访时的住院情况和临床疾病活动性。在多变量分析中,女性性别和临床疾病活动性是导致严重疲劳的独立风险因素(表 2)。 疲劳的原因是多方面的,不仅包括与 IBD 相关的临床生物因素,还包括社会、地理和睡眠障碍等方面。这强调了对 IBD 患者进行整体管理的必要性。
{"title":"P195 Prevalence and factors associated with fatigue in patients with inflammatory bowel disease","authors":"H. Kallel, N. Elleuch, R. Limam, W. Dahmeni, A. Hammami, A. Braham, A. Ben Slama, H. Jaziri, M. Ksiaa","doi":"10.1093/ecco-jcc/jjad212.0325","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.0325","url":null,"abstract":"\u0000 \u0000 \u0000 Inflammatory bowel disease (IBD) is a group of pathologies characterized by symptoms that can be distressing and incapacitating. Fatigue is one of the complaints most frequently reported by patients. However, few studies have analyzed the determinants of fatigue in IBD. The aim of our work is to estimate the prevalence of fatigue, and to identify the factors associated with it in IBD patients.\u0000 \u0000 \u0000 \u0000 Fatigue and nine other dimensions of IBD-related disability were assessed in a cross-sectional survey, including patients followed and hospitalized between March and September 2023, using the IBD-Disk questionnaire. Fatigue and severe fatigue were defined by an \"Energy\" sub-score > 5 and > 7 respectively. The correlation between Energy and the other IBD-Disk items was analyzed using Pearson's correlation coefficient. Determinants of fatigue were assessed using the Chi-2 test and multinomial logistic regression.\u0000 \u0000 \u0000 \u0000 We included 166 patients, 53.6% were men, and 69.3% were Crohn's disease carriers. Mean age was 39 ± 12.7 years. More than two-thirds (69.9%) lived in urban areas. IBD was active in 48.8% of cases. A total of 59% of patients were on biotherapy for maintenance treatment. The mean IBD-Disk total score was 36.4 ± 21. The Energy subscore obtained the highest score (4.9 ± 2.9). The prevalence rates for fatigue and severe fatigue were 42.2% and 22.9% respectively. Significant correlations were observed between fatigue and all other dimensions of IBD-related disability assessed by the IBD-Disk (p<0.001). The strongest correlations were observed between fatigue and defecation regulation (r=0.642), fatigue and work and study (r=0.630), and between fatigue and sleep (r=0.620) (Table 1). In univariate analysis, factors significantly associated with fatigue and severe fatigue were female gender (p=0.040 and 0.047 respectively), disease activity and hospitalization (p<0, 001 each), anemia (p=0.005 and 0.014 respectively), elevated CRP (p<0.001 and 0.030 respectively), hypoalbuminemia (p<0.001 and 0.042 respectively) and absence of biotherapy treatment (p=0.02 and 0.01 respectively). Living in an urban area was also associated with fatigue (p=0.015). In multivariate analysis, the independent risk factors predictive of fatigue were female gender, urban origin, hospitalization at the time of interview, and clinical disease activity. Independent risk factors for severe fatigue in multivariate analysis were female gender and clinical disease activity (Table 2).\u0000 \u0000 \u0000 \u0000 The causes of fatigue are multiple and go beyond the clinico-biological elements associated with IBD, also encompassing social, geographical and sleep disturbance aspects. This underlines the need for a holistic approach to the management of IBD patients.\u0000 \u0000 \u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"9 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P1095 Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide cohort study 2003-2021 P1095 炎症性肠病对急性冠状动脉综合征风险的影响:2003-2021年瑞典全国队列研究
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.1225
C. Eriksson, J. Sun, M. Bryder, G. Bröms, Å. H. Everhov, A. Forss, T. Jernberg, J. Ludvigsson, O. Olén
There are conflicting data on the risk of acute coronary syndrome (ACS) in patients with inflammatory bowel disease (IBD) and only a few previous reports include patients diagnosed in the last decade. The aim of this study was to assess the risk of ACS in a modern population of IBD patients vs general population comparators. In this cohort study, we used nationwide registers to identify patients diagnosed with IBD in Sweden 2003-2021. Every patient was matched by birth year, sex, calendar year of diagnosis, and area of residence with up to ten general population comparators. The primary outcome was incident ACS (i.e. ST-segment elevation myocardial infarction [MI], non–ST-segment elevation MI, unspecific MI and unstable angina). Cox proportional hazard models were used to estimate hazard ratios (HRs). Overall, 76,517 patients with IBD (Crohn's disease (CD), N=22,732; ulcerative colitis (UC), N=42,194 and IBD-unclassified, N=11,591) and 757,141 comparators were identified (Table 1). During a median follow-up of 8 years, 2546 patients with IBD (37.5/10,000 person-years) were diagnosed with ACS as compared with 19,598 (28.0/10,000 person-years) in the general population comparators. This corresponded to an HR of 1.30 (95% confidence interval [CI]: 1.24-1.35) after adjustings for potential confounders, and approximately 1 extra case of ACS in 100 IBD patients followed for 10 years. HRs for ACS were higher during the first year of follow-up but remained increased even after 5 years of follow-up (Figure 1). The highest HRs for ACS were observed in patients with elderly onset IBD (≥60 years; HR: 1.35; 95% CI: 1.28-1.43) and in patients with CD and UC with extra-intestinal manifestations (HR in CD: 1.58; 95% CI: 1.20-2.09; HR in UC: 1.98; 95% CI: 1.63-2.40). When restricting analyes to patients with elderly onset IBD, the absolute risk increase corresponded to 1 additional case of ACS for every 30 IBD-patient followed for 10 years. In contrast, no increased HRs were observed in patients diagnosed with IBD before the age of 40. But of note, just a few of the patients diagnosed with IBD before 40 years of age were followed-up beyond 50 years of age. HRs for ACS were stable during the whole study period 2003-2021 with no signs of leveling off during recent years. In this contemporary cohort of patients with IBD, exposed to modern IBD-care, an increased risk for ACS was observed as compared with individuals of the general population. The highest HRs were observed in patients with elderly onset IBD and in patients with CD and UC with extra-intestinal manifestations.
关于炎症性肠病(IBD)患者罹患急性冠状动脉综合征(ACS)的风险,目前尚存在相互矛盾的数据,而且之前只有少数几份报告包括了在过去十年中确诊的患者。本研究的目的是评估现代 IBD 患者与普通人群对比的 ACS 风险。 在这项队列研究中,我们使用全国范围的登记册来识别 2003-2021 年间在瑞典确诊的 IBD 患者。每位患者都根据出生年份、性别、诊断日历年和居住地区与多达 10 个普通人群比较者进行了匹配。主要研究结果为突发急性心肌梗死(即 ST 段抬高型心肌梗死、非 ST 段抬高型心肌梗死、非特异性心肌梗死和不稳定型心绞痛)。Cox比例危险模型用于估算危险比(HRs)。 总体而言,共确定了 76517 名 IBD 患者(克罗恩病(CD),22732 人;溃疡性结肠炎(UC),42194 人;未分类 IBD,11591 人)和 757141 名比较者(表 1)。在中位随访 8 年期间,有 2546 名 IBD 患者(37.5/10,000 人-年)被诊断为 ACS,而普通人群参照者中有 19598 人(28.0/10,000 人-年)被诊断为 ACS。在对潜在的混杂因素进行调整后,这相当于 1.30(95% 置信区间 [CI]:1.24-1.35)的 HR 值,即每 100 名随访 10 年的 IBD 患者中约多 1 例 ACS 患者。随访第一年的 ACS HR 值较高,但随访 5 年后仍保持上升趋势(图 1)。老年 IBD 患者(≥60 岁;HR:1.35;95% CI:1.28-1.43)以及有肠道外表现的 CD 和 UC 患者的 ACS HRs 最高(CD 患者 HR:1.58;95% CI:1.20-2.09;UC 患者 HR:1.98;95% CI:1.63-2.40)。如果只对老年 IBD 患者进行分析,绝对风险的增加相当于每 30 名 IBD 患者每随访 10 年就会增加 1 例 ACS。相比之下,在 40 岁之前被诊断出患有 IBD 的患者的 HRs 没有增加。但值得注意的是,只有少数在 40 岁前被诊断为 IBD 的患者在 50 岁以后接受了随访。在整个研究期间(2003-2021 年),ACS 的 HRs 保持稳定,近年来没有趋于平稳的迹象。 与普通人群相比,在这批接受现代 IBD 护理的当代 IBD 患者中,发现发生 ACS 的风险有所增加。在老年 IBD 患者以及有肠道外表现的 CD 和 UC 患者中,观察到的死亡率最高。
{"title":"P1095 Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide cohort study 2003-2021","authors":"C. Eriksson, J. Sun, M. Bryder, G. Bröms, Å. H. Everhov, A. Forss, T. Jernberg, J. Ludvigsson, O. Olén","doi":"10.1093/ecco-jcc/jjad212.1225","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.1225","url":null,"abstract":"\u0000 \u0000 \u0000 There are conflicting data on the risk of acute coronary syndrome (ACS) in patients with inflammatory bowel disease (IBD) and only a few previous reports include patients diagnosed in the last decade. The aim of this study was to assess the risk of ACS in a modern population of IBD patients vs general population comparators.\u0000 \u0000 \u0000 \u0000 In this cohort study, we used nationwide registers to identify patients diagnosed with IBD in Sweden 2003-2021. Every patient was matched by birth year, sex, calendar year of diagnosis, and area of residence with up to ten general population comparators. The primary outcome was incident ACS (i.e. ST-segment elevation myocardial infarction [MI], non–ST-segment elevation MI, unspecific MI and unstable angina). Cox proportional hazard models were used to estimate hazard ratios (HRs).\u0000 \u0000 \u0000 \u0000 Overall, 76,517 patients with IBD (Crohn's disease (CD), N=22,732; ulcerative colitis (UC), N=42,194 and IBD-unclassified, N=11,591) and 757,141 comparators were identified (Table 1). During a median follow-up of 8 years, 2546 patients with IBD (37.5/10,000 person-years) were diagnosed with ACS as compared with 19,598 (28.0/10,000 person-years) in the general population comparators. This corresponded to an HR of 1.30 (95% confidence interval [CI]: 1.24-1.35) after adjustings for potential confounders, and approximately 1 extra case of ACS in 100 IBD patients followed for 10 years. HRs for ACS were higher during the first year of follow-up but remained increased even after 5 years of follow-up (Figure 1). The highest HRs for ACS were observed in patients with elderly onset IBD (≥60 years; HR: 1.35; 95% CI: 1.28-1.43) and in patients with CD and UC with extra-intestinal manifestations (HR in CD: 1.58; 95% CI: 1.20-2.09; HR in UC: 1.98; 95% CI: 1.63-2.40). When restricting analyes to patients with elderly onset IBD, the absolute risk increase corresponded to 1 additional case of ACS for every 30 IBD-patient followed for 10 years. In contrast, no increased HRs were observed in patients diagnosed with IBD before the age of 40. But of note, just a few of the patients diagnosed with IBD before 40 years of age were followed-up beyond 50 years of age. HRs for ACS were stable during the whole study period 2003-2021 with no signs of leveling off during recent years.\u0000 \u0000 \u0000 \u0000 In this contemporary cohort of patients with IBD, exposed to modern IBD-care, an increased risk for ACS was observed as compared with individuals of the general population. The highest HRs were observed in patients with elderly onset IBD and in patients with CD and UC with extra-intestinal manifestations.\u0000 \u0000 \u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"39 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
N17 Exploration of medication non-adherence in Inflammatory Bowel Disease patients: A systematic review N17 探讨炎症性肠病患者不遵医嘱用药的情况:系统回顾
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.1389
K. King, C. Norton, T. Chalder, W. Czuber-dochan
Inflammatory bowel disease (IBD) has recognised medications to maintain remission and prevent relapse. Yet between 53–75% of people with IBD do not take medications as prescribed. Identifying and improving medication adherence in IBD is a primary treatment goal to keep symptoms quiescent. This systematic review aims to identify why people are adherent and non-adherent to IBD medications. Studies exploring medication adherence for IBD conducted between 2012-2022, were identified in six electronic databases. The quality of quantitative and qualitative studies was assessed using a scoring system or the Critical Appraisal Skills Programme, respectively. 39,603 participants were included across 79 studies investigating IBD medication adherence, mainly from single outpatient clinic populations, using cross-sectional surveys. Most data were quantitative, rated medium quality. Few studies were based around a theory to explain adherence. Non-adherence was most typically measured using a version of the Morisky Medication Adherence Scale or the study’s own self-report questionnaire, with non-adherence ranging from 4.3%-88.9%. In multivariable analysis of quantitative data, younger age and female gender were usually associated with non-adherence. The presence of smoking, psychological issues (depression, treatment concerns, anxiety) or lower social status were also significant non-adherence risk factors. Most typically investigated were clinical variables, many being significantly related with non-adherence, including medication type (specifically 5-ASA), route (oral, rectal, subcutaneous, intravenous), high and low disease activity and poor disease/medication knowledge. Significant results were often contradictory between studies, as was the relationship direction with non-adherence. Forgetting medication was the main reason for non-adherence in qualitative interviews, with side effects, costs, medication concerns and busy lifestyle also variables. Cohort-specific factors were reported for non-adherence in pregnant women, adolescents and patients during COVID.Conclusion Adherence to treatment is essential in IBD. Yet a large and confusing literature exists regarding factors underpinning non-adherence. Clinicians should be aware of those non-modifiable factors, to help identify relevant patients and support their treatment programme. Potentially modifiable factors including medication regimes, route and patient knowledge, could be targeted to improve adherence in IBD. Theoretically informed interventions need to be developed. A successful evidence-based intervention supporting medication adherence could help improve quality of life for patients living with IBD, whilst providing patient-centred care and minimising health costs.
炎症性肠病(IBD)有公认的药物来维持缓解和预防复发。然而,53%-75% 的 IBD 患者并没有遵医嘱服药。确定并改善 IBD 患者的服药依从性是保持症状稳定的首要治疗目标。本系统综述旨在确定 IBD 患者坚持或不坚持服药的原因。 我们在六个电子数据库中找到了 2012-2022 年间进行的探讨 IBD 药物依从性的研究。定量和定性研究的质量分别采用评分系统或批判性评估技能计划进行评估。 79项研究共纳入了39,603名参与者,这些研究采用横断面调查的方式调查了IBD患者的用药依从性,这些患者主要来自单个门诊诊所人群。大部分数据为定量数据,质量中等。很少有研究基于某种理论来解释服药依从性。不依从性最典型的测量方法是莫里斯基用药依从性量表或研究者自己的自我报告问卷,不依从性从4.3%-88.9%不等。在对定量数据进行多变量分析时,年轻和女性通常与不依从性有关。吸烟、心理问题(抑郁、对治疗的担忧、焦虑)或社会地位较低也是不坚持治疗的重要风险因素。最典型的调查对象是临床变量,其中许多变量与不依从性显著相关,包括药物类型(特别是 5-ASA)、途径(口服、直肠、皮下、静脉注射)、疾病活动性高低以及疾病/用药知识贫乏。不同研究之间的重要结果往往相互矛盾,与不依从性的关系方向也是如此。在定性访谈中,忘带药物是不坚持用药的主要原因,副作用、费用、用药顾虑和繁忙的生活方式也是可变因素。据报道,孕妇、青少年和 COVID 期间的患者不坚持用药的特定因素。结论 坚持治疗对 IBD 患者至关重要,但关于不坚持治疗的因素,存在大量令人困惑的文献。临床医生应了解这些不可改变的因素,以帮助识别相关患者并支持他们的治疗方案。可以针对潜在的可改变因素(包括用药方案、途径和患者知识)来改善 IBD 患者的依从性。需要制定有理论依据的干预措施。支持坚持用药的成功循证干预措施有助于提高 IBD 患者的生活质量,同时提供以患者为中心的护理并最大限度地降低医疗成本。
{"title":"N17 Exploration of medication non-adherence in Inflammatory Bowel Disease patients: A systematic review","authors":"K. King, C. Norton, T. Chalder, W. Czuber-dochan","doi":"10.1093/ecco-jcc/jjad212.1389","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.1389","url":null,"abstract":"\u0000 \u0000 \u0000 Inflammatory bowel disease (IBD) has recognised medications to maintain remission and prevent relapse. Yet between 53–75% of people with IBD do not take medications as prescribed. Identifying and improving medication adherence in IBD is a primary treatment goal to keep symptoms quiescent.\u0000 This systematic review aims to identify why people are adherent and non-adherent to IBD medications.\u0000 \u0000 \u0000 \u0000 Studies exploring medication adherence for IBD conducted between 2012-2022, were identified in six electronic databases.\u0000 The quality of quantitative and qualitative studies was assessed using a scoring system or the Critical Appraisal Skills Programme, respectively.\u0000 \u0000 \u0000 \u0000 39,603 participants were included across 79 studies investigating IBD medication adherence, mainly from single outpatient clinic populations, using cross-sectional surveys.\u0000 Most data were quantitative, rated medium quality. Few studies were based around a theory to explain adherence.\u0000 Non-adherence was most typically measured using a version of the Morisky Medication Adherence Scale or the study’s own self-report questionnaire, with non-adherence ranging from 4.3%-88.9%.\u0000 In multivariable analysis of quantitative data, younger age and female gender were usually associated with non-adherence. The presence of smoking, psychological issues (depression, treatment concerns, anxiety) or lower social status were also significant non-adherence risk factors. Most typically investigated were clinical variables, many being significantly related with non-adherence, including medication type (specifically 5-ASA), route (oral, rectal, subcutaneous, intravenous), high and low disease activity and poor disease/medication knowledge. Significant results were often contradictory between studies, as was the relationship direction with non-adherence.\u0000 Forgetting medication was the main reason for non-adherence in qualitative interviews, with side effects, costs, medication concerns and busy lifestyle also variables.\u0000 Cohort-specific factors were reported for non-adherence in pregnant women, adolescents and patients during COVID.Conclusion\u0000 Adherence to treatment is essential in IBD. Yet a large and confusing literature exists regarding factors underpinning non-adherence.\u0000 Clinicians should be aware of those non-modifiable factors, to help identify relevant patients and support their treatment programme.\u0000 Potentially modifiable factors including medication regimes, route and patient knowledge, could be targeted to improve adherence in IBD.\u0000 Theoretically informed interventions need to be developed. A successful evidence-based intervention supporting medication adherence could help improve quality of life for patients living with IBD, whilst providing patient-centred care and minimising health costs.\u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"38 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P1219 Changes in gut microbiota of patients with inflammatory bowel disease receiving biologic therapy P1219 接受生物疗法的炎症性肠病患者肠道微生物群的变化
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.1349
W. C. Tai, C. C. Yao, Y. -. Tsai
Inflammatory bowel disease (IBD), comprising the predominant forms Crohn’s disease (CD) and ulcerative colitis (UC), is associated with compositional and metabolic changes in the intestinal dysbiosis. The aim of this study is to evaluate the composition in the microbiota of IBD patients who received biologic therapy This is a prospective study recruited 14 patients with IBD received biologic therapy and 13 IBD controls who received conventional treatment . The taxonomic composition of the gut microbiota was determined by 16S ribosomal RNA gene sequencing of stool samples. The stool samples at baseline, weeks 6 and 48 after biologic therapy initiation were assessed. We also evaluated the level of inflammation and treatment response of biologics by BD activity score (CD patient by Crohn’s disease activity index [CDAI] and in UC patient by Mayo score). In CD group, we recruited 7 CD patients receiving biologic therapy (Anti-tumor Necrosis Factor for 4 and anti-integrin for 3) and 6 controls.In UC group, we recruited 7 UC patient receiving biological therapy (Anti-tumor Necrosis Factor for 2 and anti-integrin for 5) and 7 controls. Community α-diversity was lower in patients at baseline of biologics group compare to controls significantly but increase abundance and richness after achieving remission in trend at week 6 and week 48, respectively. In Top 10 taxon bacterial distribution, the Firmicutes were increase its abundances gradually ( relative abundance in biologics W0,W6,W48 and controls were 46.3%, 51.7%,62.0%, and 66.4%, respectively). Conversely, the Bacteroidetes were decrease its abundances ( relative abundance in biologics W0,W6,W48 and controls were18.3%, 18.8%, 10.2% and 6.4%, respectively). Increased F/B ratio significantly after biologics therapy also found in our study. (F/B ratio were 9.4, 12.5,64.0,and 84.3,respectively). Patients in control group had higher abundance of Firmicutes of the phylum.By contrast, Enterobacteriaceae and Bacteroidaceae were significantly more abundant in patients of biologics group at W0 . Treatment with biologic therapy induced improvement of community diversity and increased F/B ratio in IBD patients which seemed correlate the level of clinical inflammation. The dysbiosis-representative bacteria, such as Enterobacteriaceae, could induce colonic inflammation,were more abundant in patients who had higher activity of IBD. Further larger prospective studies are needed to determine whether the biologic therapy could induce long-term changes of intestinal microbiome.
炎症性肠病(IBD)主要包括克罗恩病(CD)和溃疡性结肠炎(UC),与肠道菌群失调的组成和代谢变化有关。这是一项前瞻性研究,共招募了 14 名接受生物疗法的 IBD 患者和 13 名接受常规治疗的 IBD 对照组患者。通过对粪便样本进行 16S 核糖体 RNA 基因测序,确定了肠道微生物群的分类组成。我们对基线、生物疗法开始后第 6 周和第 48 周的粪便样本进行了评估。我们还通过 BD 活动评分评估了炎症水平和对生物制剂的治疗反应(CD 患者通过克罗恩病活动指数 [CDAI] 评估,UC 患者通过梅奥评分评估)。 在 CD 组中,我们招募了 7 名接受生物制剂治疗(抗肿瘤坏死因子 4 和抗整合素 3)的 CD 患者和 6 名对照组;在 UC 组中,我们招募了 7 名接受生物制剂治疗(抗肿瘤坏死因子 2 和抗整合素 5)的 UC 患者和 7 名对照组。与对照组相比,生物制剂组患者在基线期的群落α多样性明显较低,但在第6周和第48周达到缓解后,群落α多样性和丰富度分别呈上升趋势。在前 10 个分类群的细菌分布中,固有菌的丰度逐渐增加(生物制剂 W0、W6、W48 和对照组的相对丰度分别为 46.3%、51.7%、62.0% 和 66.4%)。相反,类杆菌的丰度则有所下降(W0、W6、W48 和对照组的相对丰度分别为 18.3%、18.8%、10.2% 和 6.4%)。我们的研究还发现,生物制剂治疗后,F/B 比值明显增加。(F/B比值分别为9.4、12.5、64.0和84.3)。相比之下,在 W0 期,生物制剂组患者的肠杆菌科和类杆菌科细菌数量明显较多。 生物制剂治疗改善了 IBD 患者的群落多样性,提高了 F/B 比率,这似乎与临床炎症程度有关。肠杆菌科等代表菌群失调的细菌可诱发结肠炎症,在 IBD 活动度较高的患者中数量更多。还需要进一步开展更大规模的前瞻性研究,以确定生物疗法是否会引起肠道微生物组的长期变化。
{"title":"P1219 Changes in gut microbiota of patients with inflammatory bowel disease receiving biologic therapy","authors":"W. C. Tai, C. C. Yao, Y. -. Tsai","doi":"10.1093/ecco-jcc/jjad212.1349","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.1349","url":null,"abstract":"\u0000 \u0000 \u0000 Inflammatory bowel disease (IBD), comprising the predominant forms Crohn’s disease (CD) and ulcerative colitis (UC), is associated with compositional and metabolic changes in the intestinal dysbiosis. The aim of this study is to evaluate the composition in the microbiota of IBD patients who received biologic therapy\u0000 \u0000 \u0000 \u0000 This is a prospective study recruited 14 patients with IBD received biologic therapy and 13 IBD controls who received conventional treatment . The taxonomic composition of the gut microbiota was determined by 16S ribosomal RNA gene sequencing of stool samples. The stool samples at baseline, weeks 6 and 48 after biologic therapy initiation were assessed. We also evaluated the level of inflammation and treatment response of biologics by BD activity score (CD patient by Crohn’s disease activity index [CDAI] and in UC patient by Mayo score).\u0000 \u0000 \u0000 \u0000 In CD group, we recruited 7 CD patients receiving biologic therapy (Anti-tumor Necrosis Factor for 4 and anti-integrin for 3) and 6 controls.In UC group, we recruited 7 UC patient receiving biological therapy (Anti-tumor Necrosis Factor for 2 and anti-integrin for 5) and 7 controls.\u0000 Community α-diversity was lower in patients at baseline of biologics group compare to controls significantly but increase abundance and richness after achieving remission in trend at week 6 and week 48, respectively. In Top 10 taxon bacterial distribution, the Firmicutes were increase its abundances gradually ( relative abundance in biologics W0,W6,W48 and controls were 46.3%, 51.7%,62.0%, and 66.4%, respectively). Conversely, the Bacteroidetes were decrease its abundances ( relative abundance in biologics W0,W6,W48 and controls were18.3%, 18.8%, 10.2% and 6.4%, respectively). Increased F/B ratio significantly after biologics therapy also found in our study. (F/B ratio were 9.4, 12.5,64.0,and 84.3,respectively).\u0000 Patients in control group had higher abundance of Firmicutes of the phylum.By contrast, Enterobacteriaceae and Bacteroidaceae were significantly more abundant in patients of biologics group at W0 .\u0000 \u0000 \u0000 \u0000 Treatment with biologic therapy induced improvement of community diversity and increased F/B ratio in IBD patients which seemed correlate the level of clinical inflammation. The dysbiosis-representative bacteria, such as Enterobacteriaceae, could induce colonic inflammation,were more abundant in patients who had higher activity of IBD. Further larger prospective studies are needed to determine whether the biologic therapy could induce long-term changes of intestinal microbiome.\u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"51 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P682 A Retrospective Comparison of Different Treatment Modalities in Patients with Chronic Pouchitis P682 对慢性胃袋炎症患者不同治疗方式的回顾性比较
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.0812
Y. Uchitel, N. A. Cohen, A. Hirsch, H. Tulchinsky, M. Zemel, N. Maharshak
Chronic pouchitis affects ~30% of patients post total colectomy with ileal pouch anal anastomosis (IPAA) surgery. Treatment with anti-TNF, anti-integrin α4β7, anti-IL-12/23, or Crohn's disease exclusion diet (CDED), have shown promise in different studies. We aimed to compare the efficacy of these treatments in a real-world context and to detect factors that can aid in treatment choices. A retrospective cohort study encompassing demographic, clinic, endoscopic, histologic and lab values of adult ulcerative colitis (UC) patients post-IPAA surgery with chronic pouchitis, treated with biologics or CDED at the Tel Aviv Medical Center. Data were collected at baseline, 12, 26, and 52 weeks of treatment. Primary outcomes were assessed using the modified Pouchitis Disease Activity Index (mPDAI). mPDAI response was defined as a reduction from baseline of ≥2 points, while mPDAI remission was defined as mPDAI response in addition to mPDAI score ≤4. Therapeutic interventions among 51 patients included CDED (n=10), vedolizumab (n=21), ustekinumab (n=7) and adalimumab (n=13) [Table 1]. At 12 and 26 weeks, overall mPDAI response rates were 52% and 48%, respectively, with no significant difference between groups. At 52 weeks, mPDAI response rates were significantly higher for ustekinumab and vedolizumab (60% and 55%, respectively) compared with adalimumab and CDED (27.3% and 0%, respectively), p=0.043. Fecal calprotectin reduction at week-26 was greatest for ustekinumab (93%), followed by vedolizumab (73%), adalimumab (55%), and CDED (-13%), p=0.003. Treatment persistence over 150 weeks was significantly higher for ustekinumab (100%) compared with adalimumab (46%), vedolizumab (33%), and CDED (20%), p<0.001 [Figure 1]. The predominant cause for treatment discontinuation was secondary loss of response (50%), followed by primary non-response and surgical complications (14.7% each), poor compliance (11.8%), side-effects (5.9%), and development of antibodies (2.9%). Patients without prior biologic or immunomodulator treatment for pouchitis had significantly higher mPDAI response rates at 12 weeks (90%, p=0.016 and 73.3%, p=0.03, respectively). Patients with surgical pouch complications showed a trend towards lower mPDAI-defined response rates at 12 weeks (25% vs. 64.7%; p = 0.064). Ustekinumab and vedolizumab demonstrate higher likelihood of maintaining long-term clinical and endoscopic response, along with greater reduction in fecal calprotectin compared with adalimumab and CDED. Biologic and immunomodulator therapy-naïve patients achieved higher induction response rates.
在接受全结肠切除术和回肠袋肛门吻合术(IPAA)手术的患者中,约有 30% 患有慢性肠袋炎。抗肿瘤坏死因子(anti-TNF)、抗整合素α4β7、抗IL-12/23或克罗恩病排除饮食(CDED)等治疗方法在不同的研究中均显示出良好的疗效。我们的目的是在现实世界中比较这些治疗方法的疗效,并发现有助于选择治疗方法的因素。 这是一项回顾性队列研究,涵盖了特拉维夫医疗中心接受生物制剂或 CDED 治疗的 IPAA 手术后伴有慢性肠袋炎的成年溃疡性结肠炎(UC)患者的人口统计学、临床、内窥镜、组织学和实验室数值。数据收集时间为基线、治疗 12 周、26 周和 52 周。mPDAI反应定义为比基线降低≥2分,而mPDAI缓解定义为除mPDAI反应外,mPDAI评分≤4分。 51例患者的治疗干预包括CDED(10例)、维妥珠单抗(21例)、乌斯特库单抗(7例)和阿达木单抗(13例)[表1]。12周和26周时,mPDAI总应答率分别为52%和48%,组间无显著差异。52周时,乌司替库单抗和维多珠单抗的mPDAI应答率(分别为60%和55%)明显高于阿达木单抗和CDED(分别为27.3%和0%),P=0.043。第26周时,乌司替尼(93%)的粪便钙蛋白减少率最高,其次是维多珠单抗(73%)、阿达木单抗(55%)和CDED(-13%),P=0.003。与阿达木单抗(46%)、维多利珠单抗(33%)和CDED(20%)相比,乌司替尼(100%)的治疗持续时间明显高于阿达木单抗(46%)、维多利珠单抗(33%)和CDED(20%),P<0.001[图1]。终止治疗的主要原因是继发性反应消失(50%),其次是原发性无应答和手术并发症(各占 14.7%)、依从性差(11.8%)、副作用(5.9%)和出现抗体(2.9%)。既往未接受过生物制剂或免疫调节剂治疗的胃袋炎患者在12周时的mPDAI应答率明显更高(分别为90%,p=0.016和73.3%,p=0.03)。有手术小袋并发症的患者在12周时的mPDAI定义应答率呈下降趋势(25% vs. 64.7%; p=0.064)。 与阿达木单抗和CDED相比,优妥单抗和维多珠单抗维持长期临床和内镜反应的可能性更高,粪便钙蛋白的降低幅度也更大。生物制剂和免疫调节剂疗法无效的患者获得的诱导应答率更高。
{"title":"P682 A Retrospective Comparison of Different Treatment Modalities in Patients with Chronic Pouchitis","authors":"Y. Uchitel, N. A. Cohen, A. Hirsch, H. Tulchinsky, M. Zemel, N. Maharshak","doi":"10.1093/ecco-jcc/jjad212.0812","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.0812","url":null,"abstract":"\u0000 \u0000 \u0000 Chronic pouchitis affects ~30% of patients post total colectomy with ileal pouch anal anastomosis (IPAA) surgery. Treatment with anti-TNF, anti-integrin α4β7, anti-IL-12/23, or Crohn's disease exclusion diet (CDED), have shown promise in different studies. We aimed to compare the efficacy of these treatments in a real-world context and to detect factors that can aid in treatment choices.\u0000 \u0000 \u0000 \u0000 A retrospective cohort study encompassing demographic, clinic, endoscopic, histologic and lab values of adult ulcerative colitis (UC) patients post-IPAA surgery with chronic pouchitis, treated with biologics or CDED at the Tel Aviv Medical Center. Data were collected at baseline, 12, 26, and 52 weeks of treatment. Primary outcomes were assessed using the modified Pouchitis Disease Activity Index (mPDAI). mPDAI response was defined as a reduction from baseline of ≥2 points, while mPDAI remission was defined as mPDAI response in addition to mPDAI score ≤4.\u0000 \u0000 \u0000 \u0000 Therapeutic interventions among 51 patients included CDED (n=10), vedolizumab (n=21), ustekinumab (n=7) and adalimumab (n=13) [Table 1].\u0000 At 12 and 26 weeks, overall mPDAI response rates were 52% and 48%, respectively, with no significant difference between groups. At 52 weeks, mPDAI response rates were significantly higher for ustekinumab and vedolizumab (60% and 55%, respectively) compared with adalimumab and CDED (27.3% and 0%, respectively), p=0.043. Fecal calprotectin reduction at week-26 was greatest for ustekinumab (93%), followed by vedolizumab (73%), adalimumab (55%), and CDED (-13%), p=0.003.\u0000 Treatment persistence over 150 weeks was significantly higher for ustekinumab (100%) compared with adalimumab (46%), vedolizumab (33%), and CDED (20%), p<0.001 [Figure 1]. The predominant cause for treatment discontinuation was secondary loss of response (50%), followed by primary non-response and surgical complications (14.7% each), poor compliance (11.8%), side-effects (5.9%), and development of antibodies (2.9%).\u0000 Patients without prior biologic or immunomodulator treatment for pouchitis had significantly higher mPDAI response rates at 12 weeks (90%, p=0.016 and 73.3%, p=0.03, respectively). Patients with surgical pouch complications showed a trend towards lower mPDAI-defined response rates at 12 weeks (25% vs. 64.7%; p = 0.064).\u0000 \u0000 \u0000 \u0000 Ustekinumab and vedolizumab demonstrate higher likelihood of maintaining long-term clinical and endoscopic response, along with greater reduction in fecal calprotectin compared with adalimumab and CDED. Biologic and immunomodulator therapy-naïve patients achieved higher induction response rates.\u0000 \u0000 \u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"64 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients P919 克罗恩病排除饮食作为难治性儿科患者的附加疗法
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.1049
L. Scarallo, S. Pochesci, L. Fioretti, M. Paci, S. Renzo, S. Naldini, L. Lacitignola, J. Barp, E. Banci, A. De Blasi, P. Lionetti
Despite the accumulating body of evidence of the efficacy and tolerability of Crohn’s disease exclusion diet (CDED) combined with partial enteral nutrition (PEN), there is still a paucity data regarding its use in combination with other medical treatments. We aimed at assessing its efficacy in re-inducing remission in pediatric CD patients experiencing disease relapse while on other maintenance therapies. This was a single-center, retrospective, observational study conducted at an Italian national referral pediatric IBD center. Incident patients who received CDED coupled with PEN in the setting of the loss of response to other maintenance therapies from January 1st, 2020 to June 30th 2023 were included. Clinical remission at the end of each phase was defined by a weighted Pediatric Crohn’s Disease Activity Index (wPCDAI) below 12.5. Biochemical remission was defined by a c-reactive protein (CRP) lower than 0.5 mg/dL. A FC lower than 150 mg/kg was used as a surrogate of mucosal improvement (MI). 25 patients (52% males) met inclusion criteria and were included in the analysis. Median disease duration at CDED+PEN initiation was 31 months (Q1-Q3: 8.4-13.8). The most frequent disease location was ileocolonic (64%), 3 (12%) patients had isolated colonic involvement. 9 (36%) patients had stricturing/penetrating phenotype. 16 patients (68%) were being treated with an anti-TNF-alpha agent, whereas 5 (20%) patients were receiving ustekinumab (Table 1). wPCDAI, CRP and FC significantly decreased after the firs 8 weeks of treatment (22.5 vs 2.5, 1 vs 0.2, 640 vs 360, p<0.001, p=0.019 and p=0.007, respectively). At the end of phase I, 19/25 (76%) of the patients achieved clinical remission, 15 (60%) patients had CRP levels within normal range and 7 (28%) of them had normalized FC. 18/25 patients (72%) had received Exclusive Enteral Nutrition (EEN) for the induction of remission at diagnosis. Patients who achieved clinical remission with the EEN course (i.e.: a wPCDAI of < 12.5 after a complete course of EEN) were more likely to achieve clinical remission when receiving CDED + PEN (11/13 vs 1/5, p=0.022). CDED coupled with PEN is a valid treatment strategy in the setting of secondary loss of response to maintenance treatments in children with CD. A previous successful course of EEN was associated with higher rates of clinical remission at the end of phase I, thereby possibly identifying a subset of “nutritional responder” patients.
尽管越来越多的证据表明克罗恩病排除饮食(CDED)与部分肠内营养(PEN)相结合具有疗效和耐受性,但有关其与其他药物治疗联合使用的数据仍然很少。我们的目的是评估 CDED 对正在接受其他维持性治疗但病情复发的儿童 CD 患者重新获得缓解的疗效。 这是一项在意大利国家儿科 IBD 转诊中心进行的单中心、回顾性、观察性研究。研究对象包括在 2020 年 1 月 1 日至 2023 年 6 月 30 日期间接受 CDED 和 PEN 治疗,但对其他维持疗法无效的患者。每个阶段结束时的临床缓解定义为加权小儿克罗恩病活动指数(wPCDAI)低于 12.5。生化缓解的定义是 c 反应蛋白(CRP)低于 0.5 毫克/分升。FC 低于 150 毫克/千克被用作粘膜改善(MI)的替代指标。 25名患者(52%为男性)符合纳入标准并被纳入分析。CDED+PEN 开始治疗时的中位病程为 31 个月(Q1-Q3:8.4-13.8)。最常见的疾病部位是回结肠(64%),3 名(12%)患者有孤立的结肠受累。9名患者(36%)有狭窄/穿透表型。16名患者(68%)正在接受抗肿瘤坏死因子-α药物治疗,5名患者(20%)正在接受乌斯特库单抗治疗(表 1)。治疗最初 8 周后,wPCDAI、CRP 和 FC 显著下降(分别为 22.5 vs 2.5、1 vs 0.2、640 vs 360,p<0.001、p=0.019 和 p=0.007)。第一阶段结束时,19/25(76%)名患者实现了临床缓解,15(60%)名患者的 CRP 水平在正常范围内,其中 7(28%)名患者的 FC 恢复正常。18/25(72%)名患者在确诊时接受了肠外营养(EEN)以诱导病情缓解。接受肠内营养治疗后获得临床缓解的患者(即:在接受一个完整疗程的肠内营养治疗后,wPCDAI<12.5)更有可能在接受CDED+PEN治疗后获得临床缓解(11/13 vs 1/5,P=0.022)。 CDED+PEN是CD患儿对维持治疗继发失效时的一种有效治疗策略。在第一阶段结束时,曾成功接受过EEN治疗的患者临床缓解率较高,因此可能会确定 "营养应答 "患者的子集。
{"title":"P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients","authors":"L. Scarallo, S. Pochesci, L. Fioretti, M. Paci, S. Renzo, S. Naldini, L. Lacitignola, J. Barp, E. Banci, A. De Blasi, P. Lionetti","doi":"10.1093/ecco-jcc/jjad212.1049","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.1049","url":null,"abstract":"\u0000 \u0000 \u0000 Despite the accumulating body of evidence of the efficacy and tolerability of Crohn’s disease exclusion diet (CDED) combined with partial enteral nutrition (PEN), there is still a paucity data regarding its use in combination with other medical treatments. We aimed at assessing its efficacy in re-inducing remission in pediatric CD patients experiencing disease relapse while on other maintenance therapies.\u0000 \u0000 \u0000 \u0000 This was a single-center, retrospective, observational study conducted at an Italian national referral pediatric IBD center. Incident patients who received CDED coupled with PEN in the setting of the loss of response to other maintenance therapies from January 1st, 2020 to June 30th 2023 were included. Clinical remission at the end of each phase was defined by a weighted Pediatric Crohn’s Disease Activity Index (wPCDAI) below 12.5. Biochemical remission was defined by a c-reactive protein (CRP) lower than 0.5 mg/dL. A FC lower than 150 mg/kg was used as a surrogate of mucosal improvement (MI).\u0000 \u0000 \u0000 \u0000 25 patients (52% males) met inclusion criteria and were included in the analysis. Median disease duration at CDED+PEN initiation was 31 months (Q1-Q3: 8.4-13.8). The most frequent disease location was ileocolonic (64%), 3 (12%) patients had isolated colonic involvement. 9 (36%) patients had stricturing/penetrating phenotype. 16 patients (68%) were being treated with an anti-TNF-alpha agent, whereas 5 (20%) patients were receiving ustekinumab (Table 1). wPCDAI, CRP and FC significantly decreased after the firs 8 weeks of treatment (22.5 vs 2.5, 1 vs 0.2, 640 vs 360, p<0.001, p=0.019 and p=0.007, respectively). At the end of phase I, 19/25 (76%) of the patients achieved clinical remission, 15 (60%) patients had CRP levels within normal range and 7 (28%) of them had normalized FC. 18/25 patients (72%) had received Exclusive Enteral Nutrition (EEN) for the induction of remission at diagnosis. Patients who achieved clinical remission with the EEN course (i.e.: a wPCDAI of < 12.5 after a complete course of EEN) were more likely to achieve clinical remission when receiving CDED + PEN (11/13 vs 1/5, p=0.022).\u0000 \u0000 \u0000 \u0000 CDED coupled with PEN is a valid treatment strategy in the setting of secondary loss of response to maintenance treatments in children with CD. A previous successful course of EEN was associated with higher rates of clinical remission at the end of phase I, thereby possibly identifying a subset of “nutritional responder” patients.\u0000 \u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"50 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P1178 Detection of occult liver disease in patients with Inflammatory Bowel Disease P1178 检测炎症性肠病患者的隐匿性肝病
Pub Date : 2024-01-01 DOI: 10.1093/ecco-jcc/jjad212.1308
P. Ladrón Abia, B. Sicilia Aladrén, J. Hernández Bernad, R. Quiñones Castro, A. Martín Izquierdo, C. Villar Lucas, M. Ibañez García, L. Hernández Villalba, B. Burgueño Gómez, M. Antona Herranz, M. Cimavilla Román, L. Aguilar Argeñal, J. Gómez Camarero
Investigation of liver disease is recommended in the ECCO Guidelines for Extraintestinal Manifestations in Inflammatory Bowel Disease (IBD). The aim of this study was to analyse the prevalence of liver disease in IBD patients, to examine the frequency of different aetiologies, and to investigate a possible correlation between the severity of liver disease and IBD. Cross-sectional descriptive study including all patients with inflammatory bowel disease (IBD) of nine hospitals in Spain. The study of liver disease was carried out in two phases: patients with FIB-4 greater than 1.3 (greater than 2 in those aged 65 years or more), as well as those with APRI greater than 0.5 and/or elevated transaminases were selected as those at risk of liver disease. In the second phase, these patients underwent a medical history, comprehensive blood tests, abdominal ultrasound with SWE elastography and Fibroscan® (including transitional elastography (TE) and Controlled Attenuation Parameter (CAP)). In total, 5302 patients were enrolled and 1640 (31%) were identified as at risk for liver disease. The University Hospital of Burgos has completed the second phase of the study in patients diagnosed with IBD between 2010 and 2021 (n=151). Of these patients, 72.2% were male and the median age was 61 years. Ulcerative colitis (57%) was the most common type of IBD and 62% of the patients were overweight or obese, while 12% of the patients had high-risk alcohol consumption. Metabolic hepatic steatosis was the most frequent cause of liver disease (35%). Moderate/severe steatosis was detected in 44.3% of patients by CAP and 24% by ultrasound. The prevalence of advanced fibrosis was 10.6% and 12% when assessed by ET and SWE, respectively. Notably, 12.6% displayed ultrasound signs of chronic liver disease. A positive correlation was found between the ET and the SWE for liver fibrosis, with a correlation coefficient of ĸ = 0.663. On univariate analysis, an increased risk of significant fibrosis (p=0.011) and moderate/severe steatosis (p=0.00) was found only in those who were overweight or obese. However, no association with severity of liver disease was found for perianal disease, use of immunosuppressants or history of previous surgery. The incidence of unrecognised liver disease in IBD patients is substantial, with metabolic hepatic steatosis being the most common cause. The severity of liver disease in these patients cannot be ignored, with one in ten patients having advanced fibrosis. In the univariate study, only obesity was found to correlate with the severity of steatosis and fibrosis, while IBD severity showed no significant association with liver disease severity.
炎症性肠病(IBD)肠道外表现 ECCO 指南建议对肝病进行调查。本研究旨在分析 IBD 患者中肝脏疾病的患病率,检查不同病因的发生频率,并研究肝脏疾病的严重程度与 IBD 之间可能存在的相关性。 横断面描述性研究包括西班牙九家医院的所有炎症性肠病(IBD)患者。肝病研究分两个阶段进行:FIB-4大于1.3(65岁或以上者大于2)以及APRI大于0.5和/或转氨酶升高的患者被选为肝病高危人群。在第二阶段,这些患者接受了病史、全面的血液检查、腹部超声波 SWE 弹性成像和 Fibroscan®(包括过渡弹性成像 (TE) 和受控衰减参数 (CAP))检查。 共有 5302 名患者参与了这项研究,其中 1640 人(31%)被确定为肝病高危人群。布尔戈斯大学医院已完成了第二阶段的研究,研究对象为 2010 年至 2021 年期间确诊的 IBD 患者(人数=151)。在这些患者中,72.2%为男性,年龄中位数为61岁。溃疡性结肠炎(57%)是最常见的 IBD 类型,62% 的患者超重或肥胖,12% 的患者高危饮酒。代谢性肝脂肪变性是最常见的肝病病因(35%)。44.3% 的患者通过 CAP 检测出中度/重度脂肪变性,24% 的患者通过超声波检测出中度/重度脂肪变性。通过 ET 和 SWE 评估,晚期纤维化的发生率分别为 10.6% 和 12%。值得注意的是,12.6%的患者显示出慢性肝病的超声征象。肝纤维化的 ET 和 SWE 呈正相关,相关系数为 ĸ = 0.663。通过单变量分析,发现只有超重或肥胖者发生明显肝纤维化(p=0.011)和中度/重度脂肪变性(p=0.00)的风险才会增加。不过,肛周疾病、使用免疫抑制剂或既往手术史与肝病严重程度没有关联。 IBD 患者未被发现的肝病发病率很高,其中最常见的原因是代谢性肝脂肪变性。这些患者肝病的严重程度不容忽视,每十名患者中就有一人患有晚期肝纤维化。在单变量研究中,只发现肥胖与脂肪变性和肝纤维化的严重程度相关,而 IBD 的严重程度与肝病严重程度无明显关联。
{"title":"P1178 Detection of occult liver disease in patients with Inflammatory Bowel Disease","authors":"P. Ladrón Abia, B. Sicilia Aladrén, J. Hernández Bernad, R. Quiñones Castro, A. Martín Izquierdo, C. Villar Lucas, M. Ibañez García, L. Hernández Villalba, B. Burgueño Gómez, M. Antona Herranz, M. Cimavilla Román, L. Aguilar Argeñal, J. Gómez Camarero","doi":"10.1093/ecco-jcc/jjad212.1308","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjad212.1308","url":null,"abstract":"\u0000 \u0000 \u0000 Investigation of liver disease is recommended in the ECCO Guidelines for Extraintestinal Manifestations in Inflammatory Bowel Disease (IBD). The aim of this study was to analyse the prevalence of liver disease in IBD patients, to examine the frequency of different aetiologies, and to investigate a possible correlation between the severity of liver disease and IBD.\u0000 \u0000 \u0000 \u0000 Cross-sectional descriptive study including all patients with inflammatory bowel disease (IBD) of nine hospitals in Spain. The study of liver disease was carried out in two phases: patients with FIB-4 greater than 1.3 (greater than 2 in those aged 65 years or more), as well as those with APRI greater than 0.5 and/or elevated transaminases were selected as those at risk of liver disease. In the second phase, these patients underwent a medical history, comprehensive blood tests, abdominal ultrasound with SWE elastography and Fibroscan® (including transitional elastography (TE) and Controlled Attenuation Parameter (CAP)).\u0000 \u0000 \u0000 \u0000 In total, 5302 patients were enrolled and 1640 (31%) were identified as at risk for liver disease. The University Hospital of Burgos has completed the second phase of the study in patients diagnosed with IBD between 2010 and 2021 (n=151). Of these patients, 72.2% were male and the median age was 61 years. Ulcerative colitis (57%) was the most common type of IBD and 62% of the patients were overweight or obese, while 12% of the patients had high-risk alcohol consumption. Metabolic hepatic steatosis was the most frequent cause of liver disease (35%).\u0000 Moderate/severe steatosis was detected in 44.3% of patients by CAP and 24% by ultrasound. The prevalence of advanced fibrosis was 10.6% and 12% when assessed by ET and SWE, respectively. Notably, 12.6% displayed ultrasound signs of chronic liver disease.\u0000 A positive correlation was found between the ET and the SWE for liver fibrosis, with a correlation coefficient of ĸ = 0.663.\u0000 On univariate analysis, an increased risk of significant fibrosis (p=0.011) and moderate/severe steatosis (p=0.00) was found only in those who were overweight or obese. However, no association with severity of liver disease was found for perianal disease, use of immunosuppressants or history of previous surgery.\u0000 \u0000 \u0000 \u0000 The incidence of unrecognised liver disease in IBD patients is substantial, with metabolic hepatic steatosis being the most common cause. The severity of liver disease in these patients cannot be ignored, with one in ten patients having advanced fibrosis. In the univariate study, only obesity was found to correlate with the severity of steatosis and fibrosis, while IBD severity showed no significant association with liver disease severity.\u0000","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":"37 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Crohn's and Colitis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1